Abstracts tagged "Clinical Response"

Abstract Number: 2400 • 2014 ACR/ARHP Annual Meeting
Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Chamaida Plasencia-Rodriguez¹, G. J. Wolbink², Charlotte L. M. Krieckaert², Eva L. Kneepkens³, Samina Turk⁴, Maria Gema Bonilla⁵, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁶, Mike T. Nurmohamed², Theo Rispens⁷, Desiree van der Kleij⁸, Teresa Jurado⁹, Emilio Martín-Mola¹⁰, Dora Pascual-Salcedo¹¹ and Alejandro Balsa¹², ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Sanquin Research, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹¹Immunology, La Paz University Hospital, Madrid, Spain, ¹²Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose: There is a growing interest about optimization of biological therapies but for now no strong evidence is available to support a tapering strategy in…
Abstract Number: 1539 • 2014 ACR/ARHP Annual Meeting
Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab
Daniela Opris¹, Diana Mazilu², Violeta Bojinca³, Andreea Borangiu², Andra Balanescu⁴, Denisa Predeteanu⁵ and Ruxandra Ionescu⁴, ¹53 Tineretului Blvd, Bl. 65, s, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ²Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Intr. Carol Knappe Nr. 9A, Sec, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁵Bld.Mircea Voda Nr 36., Bl M6,, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania
Background/Purpose Debate is still ongoing regarding rituximab (RTX) as a first or second line biologic therapy. The objective of present study is to assess correlations between…
Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Eun Young Lee⁸, Francisco G. Medina-Rodriguez⁹, Pavel Shesternya¹⁰, Sebastiao Radominski¹¹, Dong Hyuk Sheen¹², Mie Jin Lim¹³, Jung-Yoon Choe¹⁴, Leysan Myasoutova¹⁵, Taek Kwon¹⁶, Sang Joon Lee¹⁶, Seung-Cheol Shim¹⁷ and Chang-Hee Suh¹⁸, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁹Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹⁰Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹¹CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹²Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁴Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹⁵City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁶CELLTRION, Inc., Incheon, South Korea, ¹⁷Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ¹⁸Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
Abstract Number: 1058 • 2014 ACR/ARHP Annual Meeting
Levels of Fatigue Are Dependent on Country of Residence in Rheumatoid Arthritis: An Analysis Among 3920 Patients from 17 Countries
Monika Hifinger^1,2, Polina Putrik^3,4, Sofia Ramiro^5,6, Maxime Dougados⁷, Laure Gossec⁸, Andras Keszei⁹, Ihsane Hmamouchi¹⁰ and Annelies Boonen¹¹, ¹Rheumatology, University of Maastricht, Maastricht, Netherlands, ²Rheumatology, MUMC, University Hospital Maastricht, Maastricht, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Health Promotion, Maastricht University, Maastricht, Netherlands, ⁵Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁷Cochin Hospital, Paris Descartes University, Paris, France, ⁸Rheumatology, Pierre et Marie Curie University, Paris, France, ⁹Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ¹⁰Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ¹¹Internal Medicine-Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: For patients with rheumatoid arthritis (RA), fatigue is an important aspect of disease which impacts quality of life. However the complex relationship between fatigue…
Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Rohit Aggarwal¹, Lisa G. Rider², Nicolino Ruperto³, Nastaran Bayat², Brian Erman⁴, Brian M. Feldman⁵, Adam M. Huber⁶, Chester V. Oddis⁷, Ingrid E. Lundberg⁸, Anthony A. Amato, MD^9,10, Robert G. Cooper, MD, FRCP¹¹, Hector Chinoy¹², Maryam Dastmalchi¹³, David Fiorentino¹⁴, David Isenberg¹⁵, James D. Katz¹⁶, Andrew L. Mammen¹⁷, Marianne de Visser¹⁸, Steven R. Ytterberg¹⁹, Katalin Danko²⁰, Luca Villa²¹, Mariangela Rinaldi²¹, Howard Rockette²², Peter A. Lachenbruch², Frederick W. Miller² and Jiri Vencovsky, MD, DSc²³, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁴Dermatology, Stanford University, Redwood City, CA, ¹⁵Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ¹⁸Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN, ²⁰Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²¹Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ²²University of Pittsburgh, Pittsburgh, PA, ²³Institute of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…
Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
Abstract Number: 2896 • 2014 ACR/ARHP Annual Meeting
a Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel^® (Tr14) and Zeel^® (Ze14) Intra‑articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee
Carlos Lozada¹, Eve del Rio², Donald Reitberg², Robert Smith², Charles Kahn³ and Roland W. Moskowitz⁴, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, ²Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, ³South Florida Rheumatology, Hollywood, FL, ⁴Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA. In response to clinician impressions of…
Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Gerd Burmester¹, Gurjit S. Kaeley², Jeffrey R. Curtis³, Yusuf Yazici⁴, Benoit Guerette⁵, Xin Wang⁵, Alan Friedman⁵ and Vibeke Strand⁶, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²College of Medicine, University of Florida, Jacksonville, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Rieke Alten¹, Robert Holt², Amy Grahn³, Patricia Rice⁴, Jeffery Kent², Frank Buttgereit⁵ and Allan Gibofsky⁶, ¹Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Medicine and Public Health, Hospital for Special Surgery, New York, NY
Background/Purpose: A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
Abstract Number: 2163 • 2013 ACR/ARHP Annual Meeting
Predictors Of No Improvement In Subjective Health Perception In Newly Diagnosed Rheumatoid Athritis Patients With a Good DAS28 Response At 12 Months In The Dutch Rheumatoid Arthritis Monitoring Tight Control Cohort
Martijn Oude Voshaar¹, Erik Taal², Peter M. ten Klooster³, Harald E. Vonkeman^2,4 and Mart A.F.J. van De Laar⁵, ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Psychology, Health and Technology, University of Twente, Enschede, Netherlands, ³Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Modern treatment strategies are highly successful in reducing disease activity in rheumatoid arthritis (RA). However, changes in clinical measures of disease activity may not…
Abstract Number: 1981 • 2013 ACR/ARHP Annual Meeting
Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis
Saad Feroz¹, Nicolino. Ruperto², Jiri Vencovsky³, Peter A. Lachenbruch¹, Brian Erman⁴, Adam Huber⁵, Brian M. Feldman⁶, Ingrid E. Lundberg⁷, Angela Pistorio⁸, Howard Rockette⁹, Frederick W. Miller¹, Rohit Aggarwal¹⁰, Lisa G. Rider¹, for The ACR-EULAR Myositis Response Criteria Project Group¹¹, Angelo Ravelli¹², Clarissa Pilkington¹³ and Sheila K. Oliveira¹⁴, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²PRINTO, IRCCS G. Gaslini, Genoa, Italy, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴SRA International, Research Triangle Park, NC, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸PRINTO, Genoa, Italy, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ¹³Rheumatology Department, Great Ormond Street Hospital, London, United Kingdom, ¹⁴Pediatric Rheumatology, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs). However, these were developed from small and partially retrospective…
Abstract Number: 1789 • 2013 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial
Karen Hambardzumyan¹, Saedis Saevarsdottir², Rebecca Bolce³, Kristina Forslind⁴, Sofia Ernestam⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, David Chernoff³, Douglas J. Haney³, Eric H. Sasso³ and Ronald F van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), clinical and radiographic predictors would be very useful for optimizing available therapies. Individual biomarkers and their combinations, such as…
Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…
Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Ingrid M. Visman¹, Inge A.M. van den Oever¹, Charlotte L. M. Krieckaert¹, Gertjan Wolbink¹ and Michael T. Nurmohamed², ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].